The Impact of Venous Invasion on the Postoperative Recurrence of pT1-3N0cM0 Gastric Cancer

被引:4
作者
Imai, Yasuo [1 ]
Kurata, Yoshihiro [2 ,3 ]
Ichinose, Masanori [2 ]
机构
[1] SUBARU Hlth Insurance Soc, Ota Mem Hosp, Dept Diagnost Pathol, 455-1 Oshima, Ota, Gunma 3738585, Japan
[2] Int Univ Hlth & Welf, Shioya Hosp, Dept Digest Surg, Yaita City, Tochigi 3292145, Japan
[3] Chiba Univ, Grad Sch Med, Dept Frontier Surg, Chiba, Chiba 2638522, Japan
关键词
gastric cancer; stomach cancer; N0; M0; venous invasion; recurrence; metastasis; adjuvant chemotherapy; EVG; CLASSIFICATION;
D O I
10.3390/jpm13050734
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The impact of venous invasion (VI) on postoperative recurrence in pathological (p)T1-3N0 clinical (c)M0 gastric cancer (GC) remains unclear. We investigated the association of VI grade with prognosis in 94 (78 stage I and 16 stage IIA) patients. VI was graded during pathological examinations based on the number of VIs per glass slide as follows: v0, 0; v1, 1-3; v2, 4-6; and v3, =7. Filling type invasion in veins with a minor axis of =1 mm increased VI grade by 1. Four (4.3%) patients experienced recurrence. Recurrence increased with pT (pT1, 0.0%; pT2, 11.1%; pT3, 18.8%) and VI grade (v0, 0.0%; v1, 3.7%, v2, 14.3%; and v3, 40.0%). Recurrence was significantly more frequent in pT3 than pT1 and in v2 + v3 than v0 (p = 0.006 and 0.005, respectively). Kaplan-Meier curve analyses demonstrated a significant decrease in recurrence-free survival according to pT (p = 0.0021) and VI grade (p < 0.0001). Multivariate Cox analysis revealed a significant association of VI grade with recurrence (p = 0.049). These results suggest that VI grade is a potential recurrence predictor for pT1-3N0cM0 GC. No recurrence can be expected in cases with pT1 or VI grade v0. Adjuvant therapy might be considered for pT3 or VI grade v2 + v3.
引用
收藏
页数:9
相关论文
共 21 条
[1]   Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial [J].
Al-Batran, Salah-Eddin ;
Homann, Nils ;
Pauligk, Claudia ;
Goetze, Thorsten O. ;
Meiler, Johannes ;
Kasper, Stefan ;
Kopp, Hans-Georg ;
Mayer, Frank ;
Haag, Georg Martin ;
Luley, Kim ;
Lindig, Udo ;
Schmiegel, Wolff ;
Pohl, Michael ;
Stoehlmacher, Jan ;
Folprecht, Gunnar ;
Probst, Stephan ;
Prasnikar, Nicole ;
Fischbach, Wolfgang ;
Mahlberg, Rolf ;
Trojan, Joerg ;
Koenigsmann, Michael ;
Martens, Uwe M. ;
Thuss-Patience, Peter ;
Egger, Matthias ;
Block, Andreas ;
Heinemann, Volker ;
Illerhaus, Gerald ;
Moehler, Markus ;
Schenk, Michael ;
Kullmann, Frank ;
Behringer, Dirk M. ;
Heike, Michael ;
Pink, Daniel ;
Teschendorf, Christian ;
Loehr, Carmen ;
Bernhard, Helga ;
Schuch, Gunter ;
Rethwisch, Volker ;
von Weikersthal, Ludwig Fischer ;
Hartmann, Joerg T. ;
Kneba, Michael ;
Daum, Severin ;
Schulmann, Karsten ;
Weniger, Joerg ;
Belle, Sebastian ;
Gaiser, Timo ;
Oduncu, Fuat S. ;
Guentner, Martina ;
Hozaeel, Wael ;
Reichart, Alexander .
LANCET, 2019, 393 (10184) :1948-1957
[2]  
American Cancer Society, STOM CANC SURV RAT
[3]   Prognostic impact of venous invasion in stage IB node-negative gastric cancer [J].
Araki, Ippeita ;
Hosoda, Kei ;
Yamashita, Keishi ;
Katada, Natsuya ;
Sakuramoto, Shinichi ;
Moriya, Hiromitsu ;
Mieno, Hiroaki ;
Ema, Akira ;
Kikuchi, Shiro ;
Mikami, Tetuo ;
Watanabe, Masahiko .
GASTRIC CANCER, 2015, 18 (02) :297-305
[4]   Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial [J].
Bang, Yung-Jue ;
Kim, Young-Woo ;
Yang, Han-Kwang ;
Chung, Hyun Cheol ;
Park, Young-Kyu ;
Lee, Kyung Hee ;
Lee, Keun-Wook ;
Kim, Yong Ho ;
Noh, Sang-Ik ;
Cho, Jae Yong ;
Mok, Young Jae ;
Kim, Yeul Hong ;
Ji, Jiafu ;
Yeh, Ta-Sen ;
Button, Peter ;
Sirzen, Florin ;
Noh, Sung Hoon .
LANCET, 2012, 379 (9813) :315-321
[5]  
Brierley JD., 2017, TNM CLASSIFICATION M
[6]  
Fukayama M., 2018, the WHO classification of tumours editorial board. WHO Classification of Tumours, Digestive System Tumours, Vfifth, P59
[7]   Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer [J].
Hironaka S. ;
Zenda S. ;
Boku N. ;
Fukutomi A. ;
Yoshino T. ;
Onozawa Y. .
Gastric Cancer, 2006, 9 (1) :14-18
[8]   Gastric cancer: Classification, histology and application of molecular pathology [J].
Hu, Bing ;
El Hajj, Nassim ;
Sittler, Scott ;
Lammert, Nancy ;
Barnes, Robert ;
Meloni-Ehrig, Aurelia .
JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2012, 3 (03) :251-261
[9]   Japanese classification of gastric carcinoma: 3rd English edition [J].
Sano T. ;
Kodera Y. .
GASTRIC CANCER, 2011, 14 (02) :101-112
[10]  
Japanese Gastric Cancer Association, 2017, JAP CLASS GASTR CARC, V15, P40